Clinical Trials to Treat Kidney (Renal Cell) Cancer

Trials 126-132 of 132
< Previous 1 ... 4 5 6

  • A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3)

    This is a Phase 1, multiple dose, ascending dose escalation study to define a MTD / RD and regimen of XmAb23104, to describe safety and tolerability, to assess PK and immunogenicity, and to preliminarily assess anti-tumor activity of XmAb23104 in subjects with selected advanced solid tumors.
    Location: Emory University Hospital / Winship Cancer Institute, Atlanta, Georgia

  • A Study of Subcutaneous Nivolumab Monotherapy With or Without Recombinant Human Hyaluronidase PH20 (rHuPH20)

    The purpose of this study is to investigate the effects of nivolumab when given under the skin with or without rHuPH20. This study will include participants with 1 of the following advanced or metastatic tumors approved for treatment with nivolumab monotherapy: - non-small cell lung cancer (NSCLC) - renal cell carcinoma (RCC) - unresectable or metastatic melanoma - hepatocellular carcinoma (HCC) - microsatellite instability-high or mismatch repair deficient colorectal cancer (MSI-H / dMMR CRC)
    Location: Emory University Hospital / Winship Cancer Institute, Atlanta, Georgia

  • Enzalutamide before Surgery in Treating Patients with Kidney Cancer

    This pilot phase 0 trial studies how well enzalutamide works before surgery in treating patients with kidney cancer. Androgens are a type of hormone produced by the body that may cause kidney tumors to grow. Anti-hormone therapy, such as enzalutamide, may lessen the amount of androgens produced by the body and keep kidney tumors from growing.
    Location: Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey

  • Ixazomib, Gemcitabine, and Doxorubicin in Treating Participants with Locally Advanced or Metastatic Kidney Cancer

    This phase II trial studies how well ixazomib, gemcitabine, and doxorubicin work in treating participants with kidney cancer that has spread to other places in the body. Ixazomib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as gemcitabine and doxorubicin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving ixazomib, gemcitabine, and doxorubicin may work better in treating participants with kidney cancer.
    Location: M D Anderson Cancer Center, Houston, Texas

  • Axitinib and L-Selenomethionine in Treating Patients with Previously Treated Advanced Metastatic Clear Cell Renal Cell Carcinoma

    This phase I trial studies the side effects and best dose of L-selenomethionine when given together with axitinib in treating patients with clear cell renal cell carcinoma that has spread from the primary site (place where it started) to other places in the body and usually cannot be cured or controlled with treatment (advanced metastatic). L-Selenomethionine may stop the growth of tumor cells by blocking the growth of new blood vessels necessary for tumor growth. Axitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving L-selenomethionine together with axitinib may be a better treatment for advanced metastatic clear cell renal cell carcinoma
    Location: University of Iowa / Holden Comprehensive Cancer Center, Iowa City, Iowa

  • Aldesleukin and Pembrolizumab in Treating Participants with Stage III and IV Melanoma and Renal Cell Cancer

    This phase I / II trial studies the side effects and how well pembrolizumab and aldesleukin work in treating participants with stage III and IV melanoma or renal cell cancer. Monoclonal antibodies, such as pembrolizumab, may interfere with the ability of tumor cells to grow and spread. Interleukins, such as aldesleukin, are proteins made by white blood cells and other cells in the body and may help regulate immune response. Giving pembrolizumab and aldesleukin may work better in treating melanoma and renal cell cancer.
    Location: University of Virginia Cancer Center, Charlottesville, Virginia

  • Atezolizumab, Entinostat, and Bevacizumab in Treating Patients with Metastatic Kidney Cancer

    This phase I / II trial studies the side effects and best dose of entinostat when given together with atezolizumab and bevacizumab and how well they work in treating patients with kidney cancer that has spread to other places in the body. Monoclonal antibodies, such as atezolizumab and bevacizumab, may interfere with the ability of tumor cells to grow and spread. Entinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving atezolizumab, entinostat, and bevacizumab may work better in treating patients with kidney cancer.
    Location: Indiana University / Melvin and Bren Simon Cancer Center, Indianapolis, Indiana


< Previous 1 ... 4 5 6